ORALLY DISINTEGRATING TABLET - MITSUBISHI TANABE PHARMA CORP

Title:

ORALLY DISINTEGRATING TABLET

Document Type and Number:

WIPO Patent Application WO/2024/053680

Kind Code:

A1

Abstract:

The present invention relates to an orally disintegrating tablet. As one embodiment, the present invention relates to an orally disintegrating tablet which comprises 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the pharmaceutically acceptable salt thereof. As another embodiment, the present invention relates to an orally disintegrating tablet which comprises 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the pharmaceutically acceptable salt thereof, an excipient, and a lubricant, and has a proper level of strength and rapid disintegrating properties in oral cavity.

More Like This:

WO/2023/133229	COMPOUNDS AND METHODS FOR MODULATING SPLICING
WO/2020/159889	SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING
WO/1999/038846	IMMUNOSUPPRESSIVE AGENTS

Inventors:

OGAWA KENICHI (JP)
KASATANI SACHIHA (JP)
ISHIDA KATSUHIRO (JP)

Application Number:

PCT/JP2023/032560

Publication Date:

March 14, 2024

Filing Date:

September 06, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

MITSUBISHI TANABE PHARMA CORP (JP)

International Classes:

A61K31/381; A61K9/20; A61K47/14; A61K47/26; A61K47/36; A61K47/38; A61P3/10

Domestic Patent References:

WO2016104643A1

2016-06-30

Foreign References:

CN104523573A	2015-04-22
JP2013526482A	2013-06-24

Other References:

SAVITHRI T B, RASHMI C, T B, , : "Research article on formulation and evaluation of fast dissolving tablets of canagliflozin by direct compression method", EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES, LAKHANI: EJBPS, vol. 7, no. 1, 1 January 2020 (2020-01-01), pages 374 - 379, XP093147394, ISSN: 2349-8870